Imagine a brain tumor that acts like a fortress, blocking the body's own immune system from attacking it. This work finds the 'secret doors' into that fortress using advanced imaging and cell mapping. By creating smarter delivery vehicles and modified immune cells, the goal is to break down those defenses and make radiation therapy actually work.
Pediatric high-grade gliomas have a very low survival rate because they are immunosuppressed and resistant to current radiotherapy. There is a critical lack of effective delivery mechanisms to get drugs past the brain's defenses.
The project is building functionalized nanocarriers for brain drug delivery, advanced CAR-T cells, and a suite of pHGG organoid and mouse models for drug screening.
If you are a cell therapy developer dealing with low CAR-T efficacy in brain tumors — this project developed more effective CAR-T cells and TME reprogramming techniques that boost anti-tumor immunity.
If you are a drug delivery specialist dealing with the blood-brain barrier — this project developed functionalized nanocarriers that target immune cells to deliver drugs directly to the brain.
If you are a radiotherapy equipment manufacturer dealing with tumor resistance — this project developed hypoxia-inducible epigenetic inhibitors that improve radiotherapy responses.
Based on available project data, specific pricing for the resulting therapies or nanocarriers is not provided; only the EU contribution of EUR 9,650,975 for research is listed.
Based on available project data, the project is currently focused on creating cellular and animal models and evaluating inhibitors, meaning it is in the pre-clinical stage rather than industrial scale.
Based on available project data, there are no specific licensing terms mentioned, though the consortium includes 1 industry partner and 1 SME likely involved in IP development.
The project runs from 2023-12-01 to 2027-11-30.
The project aims to pave the way for new clinical trials by combining TME reprogramming, radiotherapy, and CAR-T cells to improve treatment efficacy.
The consortium is heavily research-driven, consisting of 11 partners across 8 countries. With 7 research institutes and 3 universities, the academic weight is high, while industrial presence is low at 9% (1 industry partner and 1 SME). This suggests the project is focused on high-risk, high-reward discovery and pre-clinical validation rather than immediate commercial rollout.
Contact the Nencki Institute of Experimental Biology (PL)
Contact us to identify licensing opportunities for the nanocarrier and CAR-T technologies.
